Axsome Therapeutics (NASDAQ:AXSM) COO Mark Jacobson Sells 233 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 233 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total transaction of $53,165.94. Following the completion of the sale, the chief operating officer directly owned 4,517 shares in the company, valued at approximately $1,030,689.06. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Axsome Therapeutics Stock Down 0.3%

AXSM stock opened at $223.06 on Wednesday. The company has a fifty day moving average price of $171.73 and a 200 day moving average price of $163.34. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $234.29. The company has a market cap of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The business had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. The company’s revenue for the quarter was up 57.4% on a year-over-year basis. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -1.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AXSM has been the subject of several research reports. UBS Group upped their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research report on Friday, April 10th. HC Wainwright set a $290.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. TD Cowen reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Friday. Morgan Stanley boosted their price objective on shares of Axsome Therapeutics from $217.00 to $242.00 and gave the company an “equal weight” rating in a research note on Tuesday. Finally, Wells Fargo & Company boosted their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and an average price target of $251.89.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Birchview Capital LP raised its stake in shares of Axsome Therapeutics by 1.0% during the 4th quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock worth $1,107,000 after buying an additional 61 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Axsome Therapeutics by 3.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock worth $351,000 after buying an additional 65 shares during the last quarter. Xponance LLC raised its stake in shares of Axsome Therapeutics by 2.4% during the 4th quarter. Xponance LLC now owns 3,265 shares of the company’s stock worth $596,000 after buying an additional 76 shares during the last quarter. Allworth Financial LP raised its stake in shares of Axsome Therapeutics by 6.6% during the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock worth $175,000 after buying an additional 89 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Axsome Therapeutics by 4.2% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 2,190 shares of the company’s stock worth $400,000 after buying an additional 89 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.